We are pleased to present below all posts archived in 'October, 2016'. If you still can't find what you are looking for, try using the search box.
31 October 2016: Proteome Sciences plc (AIM:PRM) is pleased to announce it has raised approximately £3.3 million, before expenses, through an oversubscribed placing for cash (“Placing”) of 65,858,100 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares" and the "Placing Shares") and a subscription (the "Subscription") of 400,000 new Ordinary Shares (the “Subscription Shares”) both at a price of 5 pence per new Ordinary Share (the Placing and Subscription together, the "Fundraise"). £2.3m has been raised utilising existing shareholder authority to allot new Ordinary Shares, the balance of £1.0m will be subject to shareholder approval at a General Meeting to be held on 29 November 2016.
Read the rest of entry »
Cardiff, UK – 18th October 2016 – EKF Diagnostics, the global in vitro diagnostics company, announces that its newly introduced Glycated Serum Protein (GSP) LiquiColor® diabetic biomarker test has been verified for use on the Siemens Vista chemistry analyzer. In a scientific poster published by scientists at the Memorial Healthcare System, Hollywood, USA , it was demonstrated that EKF’s GSP assay enhances the versatility of the Vista system for the specialized glycemic monitoring of diabetics with hemoglobinopathies, or conditions that affect red blood cell (RBC) lifespan.
Results highlight need for tools to help identify patients who may benefit from chemotherapy
LONDON, [October 10, 2016] – Results from a large-scale observational study1, presented at the European Society for Medical Oncology (ESMO) annual meeting, October 7 – 11 in Copenhagen, Denmark, showed outcomes disparities in breast cancer-specific mortality between patients 70 years or greater and those under 70 with a higher breast cancer mortality for the older patients.
Mologic Ltd, headquartered in Bedfordshire, is pleased to announce the opening of its new manufacturing facility.
Set up for small-scale LFD production (5,000 per lot, 500,000 per year) we have some capacity available for contract work.
Please contact David Hall on 01234 780020 or check our website for more details: www.mologic.co.uk
Cardiff, UK, October 10, 2016 – BBI Solutions OEM Ltd (BBI) (www.bbisolutions.com), the leading provider of lateral flow diagnostics and biological raw materials, announced the successful acquisition of its previous joint venture with Novarum DX Ltd - a developer of smart phone applications for reading diagnostic tests, in line with the company's expansion plans.
Oxford, UK – 11 October 2016
Oxford Gene Technology (OGT), The Molecular Genetics Company, has today announced a significant expansion of its existing catalogue of Cytocell Aquarius® Haematology probes for fluorescence in situhybridisation (FISH) — underlining the company's position as the one-stop-shop for high-quality FISH probes. These additions have been introduced due to an ongoing commitment to use customer input as a major driver for the rapid development of the latest research-relevant probes.
10th October 2016
Abingdon Health announce the CE marking of Seralite®-FLC ELISA, the latest addition to the Seralite® range. The introduction of an ELISA assay to measure serum free kappa and free lambda light chains means Abingdon Health now has the opportunity to offer its customers a simple, high throughput method for detecting and measuring serum FLC levels.
BÜHLMANN has introduced the first rapid test to measure infliximab trough level in patient’s serum, on the Quantum Blue® platform. Exclusively available in the UK from Alpha Laboratories, Quantum Blue infliximab enables responsive anti-TNFα drug optimisation, maximising the benefit of costly biologic therapies.
Biofortuna Ltd, a UK-based diagnostics company offering molecular diagnostic products and contract manufacturing services, has successfully achieved key milestones in the development of its new blood group genotyping product family – ReadyPlex™. This breakthrough has released the second tranche of its 2015 funding – totalling £1.5m – which will be used for final development and commercialisation of this innovative product line.
Who are the BIVDA Members
Member Press Releases
Point of Care Directory
News, Policy and Media
BIVDA Press Releases